ICN PHARMACEUTICAL MERGING AFFILIATES TO REDUCE COSTS
ICN PHARMACEUTICAL MERGING AFFILIATES TO REDUCE COSTS, simplify corporate structure, streamline management and eliminate duplicate functions, the firm announced Aug. 2. ICN and its three affiliates -- Viratek, SPI Pharmaceuticals and ICN Biomedicals -- will consolidate into a single entity under the name ICN Pharmaceuticals. In addition to lowering general and administrative expenses, the Costa Mesa, Calif.-based company expects the new combination will "reduce significantly certain income taxes.... [by permitting] the use of net operating loss carry-forwards."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth